Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 3(2)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05295459Phase 3Completed

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

Role: lead

NCT05219968Phase 3Completed

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

Role: lead

NCT05035654Phase 2Completed

LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)

Role: lead

NCT04041609Phase 2Completed

LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)

Role: lead

NCT02967731Phase 1Completed

480 Biomedical Sinus Drug Depot

Role: lead

All 5 trials loaded